Clinical Trial Update: Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status [Phase 2]

View source ↗

Summary

Phase 2 trial update on olaparib tablets for ovarian cancer with varying homologous recombination deficiency (HRD) status shows completed results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Olaparib (Olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity | Phase 2 | Status: COMPLETED | Results posted: 2022-04-13